Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration

Gan & Lee Pharmaceuticals (SHA: 603087) has announced that China’s National Medical Products Administration (NMPA) has granted clinical trial approval for GLR1062, a first-in-class gene therapy for the treatment of adult neovascular (wet) age-related macular degeneration (nAMD). The investigational therapy utilizes a recombinant adeno-associated virus (rAAV) delivery vector to express a vascular endothelial growth factor (VEGF) antagonist in vivo via intraocular injection, representing a potentially transformative approach to managing this leading cause of vision loss in elderly populations.

Regulatory Milestone

Therapeutic Profile & Mechanism of Action

Gene Therapy Platform

• Vector: Recombinant adeno-associated virus (rAAV) – established safety profile in ocular gene therapy
• Transgene: VEGF antagonist designed for sustained intraocular expression
• Delivery: Single intravitreal injection providing long-term therapeutic protein production
• Mechanism: Continuous endogenous production of VEGF antagonist maintains therapeutic levels without repeated injections

Clinical Rationale

• Current Standard of Care: Monthly or bimonthly anti-VEGF injections requiring lifelong treatment burden
• Treatment Gap: ~50% of patients experience suboptimal response or treatment fatigue with current regimens
• Therapeutic Goal: Single-administration therapy providing sustained VEGF suppression for years
• Patient Benefit: Eliminates need for frequent intravitreal injections and associated complications

Market Context & Unmet Medical Need

nAMD Landscape in China

• Prevalence: Estimated 4-5 million nAMD patients in China, growing with aging population
• Annual Incidence: ~500,000 new cases annually
• Current Treatment Burden: Patients require 6-12 intravitreal injections per year indefinitely
• Healthcare System Impact: Significant resource utilization from frequent clinic visits and injections

Global Gene Therapy Context

• Pioneering Status: No rAAV-VEGF antagonist gene therapy approved anywhere globally
• Competitive Landscape: Multiple gene therapy approaches in development but none with NMPA/EMA/FDA approval
• First-Mover Advantage: Potential to establish dominant position in emerging nAMD gene therapy market
• Pricing Premium: Gene therapies typically command premium pricing reflecting curative potential

Strategic Implications for Gan & Lee Pharmaceuticals

• Innovation Leadership: Transforms company from traditional pharmaceutical manufacturer to gene therapy innovator
• Platform Technology: Establishes rAAV gene therapy capabilities for future ophthalmology and CNS applications
• Global Ambition: First-in-class status supports international regulatory filings and partnership opportunities
• Portfolio Diversification: Expands beyond diabetes and cardiovascular franchises into high-value specialty therapeutics

“This NMPA approval for GLR1062 represents a groundbreaking moment for both Gan & Lee and Chinese patients with wet AMD,” said Dr. Li Guohui, Chairman and CEO of Gan & Lee Pharmaceuticals. “By harnessing gene therapy to provide sustained VEGF suppression from a single injection, we aim to eliminate the treatment burden that currently defines nAMD management while potentially improving visual outcomes.”

Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development plans, regulatory approvals, and therapeutic potential. Actual results may differ due to risks including clinical trial outcomes, safety concerns inherent in gene therapy, regulatory requirements, and competitive developments in the rapidly evolving nAMD treatment landscape.-Fineline Info & Tech